USA flag logo/image

An Official Website of the United States Government

SBIR Phase I:Novel System for Targeting Nanobodies

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
99001
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
1013327
Solicitation Year:
N/A
Solicitation Topic Code:
BT7
Solicitation Number:
N/A
Small Business Information
Alpha Universe LLC
1202 Ann Street Madison, WI 53713-2410
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: SBIR Phase I:Novel System for Targeting Nanobodies
Agency: NSF
Contract: 1013327
Award Amount: $149,997.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project has the goal of creating a system that, while being inexpensive and simple to use, will be able to generate variable domains of heavy chain-only llama antibodies (also called VHHs, or nanobodies) targeted to antigens of interest in vitro. This system will not require llama vaccinations and will use universal pre-fabricated libraries for fast isolation of nanobodies with required specificities. To prove the concept, it is proposed to create the first set of nanobodies targeted at the catalytic domain of botulinum neurotoxin A, which is listed among the most potent biothreat agents and, simultaneously, is used as a miracle drug in neurology and cosmetology. The broader/commercial impacts of this research are expected in the areas of biodefense and medicine. Our system will allow fast and inexpensive development of nanobodies produced in E. coli and specifically targeted to antigens of choice. Availability of such small and stable antigen-targeted molecules will stimulate their use as substitutes for antibodies in multiple detection and diagnostic techniques. Our system will provide potential for development of new ways for isolation, immobilization and/or inactivation of biologically active agents. Additionally, the ability to quickly generate nanobodies with new specificities will speed up efforts to develop nanobodies into a new class of drugs for treatment of both infectious and non infectious diseases.

Principal Investigator:

Alexey G. Zdanovsky
PhD
6086610861
alexeyzd@tds.net

Business Contact:

Alexey G. Zdanovsky
PhD
6086610861
alexeyzd@tds.net
Small Business Information at Submission:

Alpha Universe
1202 Ann Street Madison, WI 53713

EIN/Tax ID: 320102198
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No